Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Democrats pounce on Arizona Supreme Court's abortion rulingMarcus Sasser leads Pistons past Mavericks 107More history for Tiger Woods. He makes the Masters cut for a record 24th time in a rowAugsburg edges closer to European spot with 2CJ McCollum scores 28 points as Pelicans hold off Warriors 114QB Kellen Mond joining the New Orleans Saints to compete for a backup roleKentucky GOP lawmakers remove Democratic governor's role in filling US Senate vacanciesLazio booed by own fans but Anderson leads from the front in 4Election 2024 poll: Americans dissatisfied with Biden, TrumpMatias Maccelli scores in OT as Coyotes beat Oilers 3
2.6733s , 6505.234375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,International Intervals news portal